Introduction {#sec1}
============

According to the WHO Global Tuberculosis Report 2014, an estimated 0.4 million people had already been diagnosed with tuberculosis (TB) but developed to be retreatment cases \[[@cit0001]\]. Tuberculosis is present in all regions of the world. India and China accounted for 22% and 15% of new and relapse cases, respectively \[[@cit0001]\]. Currently, more than 85% of initial patients are cured in China, with an increase in coverage of directly observed treatment short course (DOTS) therapy \[[@cit0002]\]. According to national tuberculosis prevalence surveys in China, the proportion treated by the public health system (using the DOTS strategy) increased from 15% in 2000 to 66% in 2010 \[[@cit0002]\]. However, there still existed massive TB retreatment of patients in China; the proportion of retreatment cases was 31% in 2010 \[[@cit0002]\], due to nosocomial transmission, the use of inadequate treatment regimens, poor management of resistant cases and the high migration rate. Moreover, with the large overall number of TB patients and the limited cure rate for TB retreatment, the high cost of retreatment should not be ignored in China.

Retreatment of TB is presenting new challenges for TB control in this context. The type of retreatment of TB included relapse, failure, treatment after loss to follow-up and other previously treated patients \[[@cit0001]\]. Relapse of TB is one of the most concerning issues \[[@cit0003]\]. The incidence of TB relapse in those who underwent previous treatment can be 30 times higher than the incidence of TB in new cases \[[@cit0004]\]. The most concerning situation is multidrug resistant (MDR) TB, the retreatment of patients who are often exposed to conditions associated with future failures that are attributable to microbial resistance. In the recent global surveillance for drug-resistant TB, it was estimated that 7.9% of relapse cases were MDR TB \[[@cit0005]\]. Retreatment patients also have a lower cure rate than new cases and experience more side effects during treatment with the second-line drugs \[[@cit0006]\].

Better understanding of the determinants of TB retreatment helps to identify those at high risk of disease retreatment and promises to reduce the disease burden through risk factor intervention. Recently, several studies have suggested that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), platelet count, plateletcrit (PCT), and platelet distribution width (PDW) may be potential biomarkers of PTB severity \[[@cit0007]--[@cit0010]\]. Among these, the neutrophil-to-lymphocyte ratio (NLR) is a readily available and cost-effective biomarker used in clinical practice that has been associated with recurrence \[[@cit0011], [@cit0012]\] and survival \[[@cit0013]--[@cit0015]\] in various diseases. However, whether NLR is a predictive factor associated with TB retreatment has not yet been ascertained. The objective of this study was to investigate the value of NLR to predict pulmonary tuberculosis (PTB) retreatment coordinated with other risk factors.

Material and methods {#sec2}
====================

Study population and ethical approval {#sec2.1}
-------------------------------------

We conducted a case-control study of all newly diagnosed cases of PTB in the clinical database of The Fifth People's Hospital of Wuxi from December 2009 to December 2011. Following the national TB guidelines, a case of PTB was defined by positive sputum smear or sputum culture or, in the absence of bacteriological evidence, positive chest X-ray compatible with PTB plus clinical improvement after anti-TB treatment. Of the 386 incident cases of PTB during the study period, we excluded patients who transferred out (*n* = 32), died during anti-TB treatment (*n* = 20) and those for whom information was missing (*n* = 28) for any other reasons during the follow-up period. After exclusion, 306 patients with complete follow-up information until December 31^st^ of 2014 were included in this study. Meanwhile, 68 patients were followed up for TB retreatment (retreatment was defined as patients undergoing the second anti-TB treatment with active PTB after previous anti-TB treatment for one month or more). The rest of the no retreatment PTB cases (*n* = 238) who had completed anti-TB treatment and were cured without retreatment were selected as controls ([Figure 1](#f0001){ref-type="fig"}). Demographic and clinical data of the 306 PTB patients were obtained in the present study ([Table I](#t0001){ref-type="table"}).

###### 

Characteristics of study participants

  Parameter                                                                                                   Patients (*n* = 306)
  ----------------------------------------------------------------------------------------------------------- ----------------------
  Age \[years\][a](#tf1-1){ref-type="table-fn"}                                                               59 (40--70)
  Sex, male[b](#tf1-2){ref-type="table-fn"}                                                                   228 (74.5)
  WBC count \[× 10^9^/l\][a](#tf1-1){ref-type="table-fn"}                                                     6.935 (5.483--8.907)
  Neutrophil count \[× 10^9^/l\][a](#tf1-1){ref-type="table-fn"}                                              4.630 (3.437--6.432)
  Lymphocyte count \[× 10^9^/l\][a](#tf1-1){ref-type="table-fn"}                                              1.497 (1.113--1.860)
  Monocyte count \[× 10^9^/l\][a](#tf1-1){ref-type="table-fn"}                                                0.462 (0.224--0.660)
  NLR[a](#tf1-1){ref-type="table-fn"}                                                                         3.124 (2.131--4.917)
  History of smoking[b](#tf1-2){ref-type="table-fn"}:                                                         
   Yes                                                                                                        150 (49.0)
   No                                                                                                         156 (51.0)
  Cancer[b](#tf1-2){ref-type="table-fn"}:                                                                     
   Yes                                                                                                        14 (4.6)
   No                                                                                                         292 (95.4)
  HIV[b](#tf1-2){ref-type="table-fn"}:                                                                        
   Yes                                                                                                        5 (1.6)
   No                                                                                                         301 (98.4)
  DM[b](#tf1-2){ref-type="table-fn"}:                                                                         
   Yes                                                                                                        32 (10.5)
   No                                                                                                         274 (89.5)
  HBV/HCV[b](#tf1-2){ref-type="table-fn"}:                                                                    
   Yes                                                                                                        37 (12.1)
   No                                                                                                         269 (87.9)
  Coexisting extra-pulmonary lesion[b](#tf1-2){ref-type="table-fn"}:                                          
   Yes                                                                                                        62 (20.3)
   No                                                                                                         244 (79.7)
  Culture positive and/or smear-positive[b](#tf1-2){ref-type="table-fn"},[\#](#tf1-3){ref-type="table-fn"}:   
   Yes                                                                                                        127 (41.5)
   No                                                                                                         160 (52.3)
  Cavitation on initial CXR[b](#tf1-2){ref-type="table-fn"},[&](#tf1-4){ref-type="table-fn"}:                 
   Yes                                                                                                        97 (31.7)
   No                                                                                                         194 (63.4)

Data are presented as numbers (%) of individuals except where indicated.

Data are presented as median value (interquartile range).

Missing information in 19 patients.

Missing information in 15 patients.

![Flow diagram for enrollment of study participants in the nested case-control study](AMS-13-27829-g001){#f0001}

This study was approved by the Institutional Ethics Committee of The Fifth People's Hospital of Wuxi, Affiliated to Jiangnan University (No: QD-2014-0023), and was in compliance with the national legislation and the Declaration of Helsinki guidelines. Because it was a retrospective review of the TB registry and medical records, informed consent was not available. All patients' records and information were anonymized and de-identified prior to analysis.

Measurement of NLR and other factors {#sec2.2}
------------------------------------

The NLR was directly calculated from peripheral blood counts. Peripheral blood collected in ethylene-diamine tetra-acetic acid (EDTA)-containing tubes was analyzed by one of two clinical diagnostic laboratories each using a five-part differential hematology analyzer (Sysmex Model XS, Hamburg, Germany). Full blood count measurement was subject to strict quality assurance procedures including twice-daily high and low internal quality control, fortnightly quality controls through the Wuxi clinical laboratory QC scheme (Wuxi, Jiangsu, China) and annual quality assurance as part of the Jiangsu clinical laboratory QC scheme. Both laboratories are accredited by the China National Accreditation System in accordance with international standards ISO 17025/2005 and ISO 15189/2007. Information on other factors was also obtained from the clinical database of the Infectious Hospital of Wuxi. We extracted the following information through medical chart review: age, sex, history of smoking, HIV status, cancer, diabetes mellitus (DM), HBV/HCV status, coexisting extra-pulmonary TB, bacteriological confirmation and cavitation on chest X-ray within 1 month of initiating anti-TB treatment.

Statistical analysis {#sec2.3}
--------------------

Statistical analysis was conducted using SPSS version 17.0. Pearson's χ^2^ test was conducted to identify significant differences across PTB retreatment cases and controls. The odds ratios (ORs) were estimated with 95% confidence intervals (CIs) from the bivariate analysis to evaluate the factors associated with PTB retreatment cases and controls. Adjusted odds ratios (AOR) with 95% CIs were estimated from the multivariate analysis to determine the factors associated with PTB retreatment. The cumulative recurrence rate during the follow-up period was calculated using Kaplan-Meier analysis, and the log-rank test was used to examine the significance of the differences between different NLR groups. *P*-value \< 0.05 was considered as statistically significant for all analyses.

Results {#sec3}
=======

The baseline characteristics of the patient population included in this study are outlined in [Table I](#t0001){ref-type="table"}. There were 306 patients enrolled in the study, with a median age of 59 years. Of the 306 patients, the majority of patients were male (74.5%). There were 150 (49%) patients with a history of smoking, 37 (12.1%) HBV/HCV-positive patients, 32 (10.5%) patients diagnosed with diabetes mellitus (DM), 14 (4.5%) patients with cancer and only 5 (1.6%) patients with HIV. There were 62 PTB patients with coexisting extra-pulmonary lesions, 127 patients bacteriologically confirmed positively and 97 patients diagnosed with cavitation on initial chest X-ray (CXR). Full blood counts were obtained for all included patients. The median WBC for the study population was 6.935 × 10^9^/l (interquartile range (IQR): 5.483--8.907 × 10^9^/l), the median neutrophil count was 4.630 × 10^9^/l (IQR: 3.437--6.432 × 10^9^/l), the median lymphocyte count was 1.497 × 10^9^/l (IQR: 1.113--1.860 × 10^9^/l), the median monocyte count was 0.462 × 10^9^/l (IQR: 0.224--0.660 × 10^9^/l) and the median NLR was 3.124 (IQR: 2.131--4.917).

We included all patients during a median follow-up period of 3.25 years (IQR: 3.0--4.1 years) (*n* = 306). The median time from first treatment to second treatment of retreatment patients was 1.25 years (IQR: 0.9--1.9 years) (*n* = 68). The rest of the PTB cases who had completed anti-TB treatment and were cured without retreatment were selected as controls (*n* = 238). According to the receiver operating characteristics (ROC) curve, the best cut-off value of NLR was 2.53, as shown in [Figure 2](#f0002){ref-type="fig"}, with a sensitivity of 70.6% and a specificity of 45.4%. Forty-eight (78%) patients had an elevated pretreatment NLR (2.53) identified in retreatment cases compared to 130 (54.6%) patients identified among controls (*p* = 0.017). The distribution of sex did not differ between cases and controls (*p* = 0.834) ([Table II](#t0002){ref-type="table"}). Compared to controls, cases were more likely to be smokers (*p* = 0.012), aged ≥ 60 (*p* = 0.001) and with initial cavitation (*p* \< 0.001). The prevalence of DM, cancer, HBV/HCV and extra-pulmonary lesion were higher among cases than controls (13.2% vs. 9.7%, 8.8% vs. 3.4%, 17.6% vs. 10.1%, 23.5% vs. 19.3%, respectively), but without significance.

###### 

Characteristics of study participants

  Parameter                                                                Cases (*N* = 68) *n* (%)   Controls (*N* = 238) *n* (%)   *P*-value[a](#tf2-1){ref-type="table-fn"}
  ------------------------------------------------------------------------ -------------------------- ------------------------------ -------------------------------------------
  NLR:                                                                                                                               
   ≥ 2.53                                                                  48 (78.0)                  130 (54.6)                     0.017
   \< 2.53                                                                 20 (22.0)                  108 (45.4)                     
  Age \[years\]:                                                                                                                     
   \< 40                                                                   7 (10.3)                   60 (25.2)                      0.001
   40--59                                                                  15 (22.1)                  75 (31.5)                      
   ≥ 60                                                                    46 (67.6)                  103 (43.3)                     
  Sex, male                                                                50 (73.5)                  178 (74.8)                     0.834
  History of smoking                                                       42 (61.2)                  106 (44.5)                     0.012
  Cancer                                                                   6 (8.8)                    8 (3.4)                        0.078
  DM                                                                       9 (13.2)                   23 (9.7)                       0.408
  HBV/HCV                                                                  12 (17.6)                  25 (10.1)                      0.125
  Coexisting extra-pulmonary lesion                                        16 (23.5)                  46 (19.3)                      0.453
  Culture positive and/or smear-positive[b](#tf2-2){ref-type="table-fn"}   32 (48.5)                  95 (42.9)                      0.431
  Cavitation on initial CXR[c](#tf2-3){ref-type="table-fn"}                32 (47.1)                  65 (29.1)                      \< 0.001

By Pearson's χ^2^ test

missing information in 2 cases and 17 controls

missing information in 15 controls.

![ROC curve of NLR between retreatment cases and no-retreatment controls](AMS-13-27829-g002){#f0002}

NLR ≥ 2.53 before anti-TB treatment was associated with retreatment of PTB both in the univariable analysis (OR = 1.994, 95% CI: 1.116--3.564) and the multivariable analysis (adjusted OR (AOR) = 2.409, 95% CI: 1.212--4.788) ([Table III](#t0003){ref-type="table"}). In the multivariable analysis we included only 66 cases and 209 controls because of missing information in the bacteriological test and the results of chest X-ray. We conducted a separate analysis using all cases and controls and adjusting for all factors except for the bacteriological test and results of chest X-ray; the association was slightly attenuated but remained statistically significant (AOR = 2.157, 95% CI: 1.143--4.072). NLR ≥ 2.53 before anti-TB treatment was a significant predictor for PTB retreatment. Additionally, cavitation on chest X-ray (OR = 2.922, 95% CI: 1.654--5.411; AOR = 2.482, 95% CI: 1.230--5.007), history of smoking (OR = 2.202, 95% CI: 1.158--3.493; AOR = 2.321, 95% CI: 1.135--4.745) and age ≥ 60 (OR = 3.828, 95% CI: 1.626--9.015; AOR = 2.931, 95% CI: 1.122--7.653) were also risk factors for PTB retreatment. Patients with cancer (AOR = 3.797, 95% CI: 1.101--13.10), HBV/HCV (AOR = 4.551, 95% CI: 1.791--11.56) and coexistence of extra-pulmonary lesions (AOR = 2.304, 95% CI: 1.073--4.974) were associated with PTB retreatment in the multivariable analyses but not in the univariable analysis. However, gender, bacteriological confirmation and DM were not confirmed to be factors associated with PTB retreatment in this study.

###### 

Univariable and multivariable odds ratios for the associations between potential risk factors and TB retreatment

  Parameter                                                                Unadjusted odds ratio (95% CI)   *P*-value   Adjusted odds ratio (95% CI)   *P*-value
  ------------------------------------------------------------------------ -------------------------------- ----------- ------------------------------ -----------
  NLR:                                                                                                                                                 
   \< 2.53                                                                 Reference                                    Reference                      
   ≥ 2.53                                                                  1.994 (1.116--3.564)             0.020       2.409 (1.212--4.788)           0.012
  Age \[years\]:                                                                                                                                       
   \< 40                                                                   Reference                                    Reference                      
   40--59                                                                  1.714 (0.657--4.474)             0.271       1.678 (0.578--4.870)           0.341
   ≥ 60                                                                    3.828 (1.626--9.015)             0.002       2.931 (1.122--7.653)           0.028
  Sex, male                                                                0.936 (0.507--1.729)             0.833       0.428 (0.190--0.963)           0.040
  History of smoking                                                       2.202 (1.158--3.493)             0.013       2.321 (1.135--4.745)           0.021
  Cancer                                                                   2.782 (0.931--8.317)             0.067       3.797 (1.101--13.100)          0.035
  DM                                                                       1.426 (0.626--3.246)             0.398       2.519 (0.981--6.466)           0.055
  HBV/HCV                                                                  1.826 (0.864--3.860)             0.115       4.551 (1.791--11.563)          0.001
  Coexisting extra-pulmonary lesion                                        1.284 (0.673--2.451)             0.448       2.304 (1.073--4.974)           0.032
  Culture positive and/or smear-positive[a](#tf3-1){ref-type="table-fn"}   1.768 (0.978--3.198)             0.059       0.755 (0.382--1.491)           0.418
  Initial cavitation[b](#tf3-2){ref-type="table-fn"}                       2.922 (1.654--5.411)             \< 0.001    2.482 (1.230--5.007)           0.011

Missing information in 19 patients (2 cases and 17 controls)

missing information in 15 patients (all controls).

When we used a different definition for PTB retreatment, the increased risk of NLR ≥ 2.53 on TB retreatment was consistently observed. The OR was largest when the date of the second treatment was defined as more than 3 months after the first treatment (AOR = 2.409, 95% CI: 1.212--4.788, [Table IV](#t0004){ref-type="table"}). The OR was almost the same when we defined the date of the second treatment as more than 6 months after the first treatment (AOR = 2.256, 95% CI: 1.128--4.512). Finally, the OR was decreased but not much when we prolonged the duration between the second and first treatment to more than 1 year (AOR = 2.191, 95% CI: 1.027--4.677). Above all, the result of increased risk of NLR ≥ 2.53 on TB retreatment was stable.

###### 

Association of NLR with TB retreatment by different definitions for TB retreatment

  Parameter                            No. of cases with NLR ≥ 2.53 *n* (%)   No. of controls with NLR ≥ 2.53 *n* (%)   Adjusted odds ratio (95% CI)
  ------------------------------------ -------------------------------------- ----------------------------------------- ------------------------------
  Three months after first treatment   48 (72.7)                              114 (54.5)                                2.409 (1.212--4.788)
  Six months after first treatment     44 (71.0)                              114 (54.5)                                2.256 (1.128--4.512)
  One year after first treatment       35 (71.4)                              114 (54.5)                                2.191 (1.027--4.677)

The retreatment rate during the follow-up among all cases is shown in [Figure 3 A](#f0003){ref-type="fig"}. The retreatment rates were 0% after 3 months, 2.9% after 6 months, 3.9% after 1 year and 6.9% after 2 years. The retreatment rate increased with the follow-up time. The retreatment rates in PTB patients with NLR ≥ 2.53 and NLR \< 2.53 are shown in [Figure 3 B](#f0003){ref-type="fig"}; they were 27.1% and 15.5%, respectively, with a significant difference (log-rank test; *p* = 0.010).

![Cumulative retreatment with months after primary treatment. **A** -- Cumulative retreatment during follow- up period in 306 PTB patients (Kaplan-Meier); **B** -- Cumulative retreatment during follow-up period in PTB patients with NLR ≥ 2.53 and NLR \< 2.53 (Kaplan-Meier) (log-rank test; *p* = 0.010)](AMS-13-27829-g003){#f0003}

Discussion {#sec4}
==========

The PTB retreatment still remains a major health problem despite an increase in coverage of DOTS therapy. Better understanding of the determinants of TB retreatment helps to identify those at high risk of retreatment disease and promises to reduce the disease burden through risk factor intervention.

White blood cell populations play an important role in the systemic inflammatory response to infection \[[@cit0016], [@cit0017]\]. Following infection, the number of circulating neutrophils increases while lymphocyte counts decrease \[[@cit0016]\]. Neutrophilia is well recognized as an infection marker, whereas absolute lymphocytopenia is ignored as a possible marker in infectious disease management. Recently, the latter showed its potential value in predicting bacteremia and the severity of several infectious diseases \[[@cit0018]--[@cit0022]\].

Combining both parameters as the ratio of neutrophil and lymphocyte counts is increasingly used in several clinical circumstances. Primarily, NLR was studied as an infection marker and found to correlate well with disease severity and outcome \[[@cit0019], [@cit0023], [@cit0024]\]. For example, NLR was reported to be significantly higher in patients with advanced PTB as opposed to patients with mild to moderate PTB \[[@cit0025]\]. Moreover, NLR may be treated as a possible marker in differentiating tuberculosis from bacterial community-acquired pneumonia (CAP) \[[@cit0026]\] and sarcoidosis \[[@cit0027]\]. Recently, NLR was suggested as a simple marker that may discriminate severe bacterial from viral infections \[[@cit0028]\]. Other studies focused on the use of the NLR in specific clinical conditions, or its use as an independent predictor of survival in patients with various conditions ranging from oncological to cardiovascular diseases \[[@cit0029]--[@cit0032]\].

The enhanced neutrophil response might promote *Mycobacterium tuberculosis* (Mtb) proliferation and transmission, and the suppression of lymphocytes might inhibit the anti-Mtb immune response and delay therapy duration, which together lead to a high NLR may be a novel index to evaluate PTB retreatment. In this case-control study, we determined NLR ≥ 2.53 as a risk factor for PTB retreatment, and, when we used a different definition for PTB retreatment, the result of increased risk of NLR ≥ 2.53 on PTB retreatment was stable. To our knowledge, we are the first to propose that NLR ≥ 2.53 is predictive of PTB retreatment. Moreover, a history of smoking, initial cavitation on chest X-ray and age ≥ 60 were also confirmed to be factors associated with PTB retreatment.

Our study also has limitations. The eligible patients represented a fraction of the patients diagnosed with active tuberculosis during the study period, raising a concern for a selection bias. As a retrospective study, collecting information from medical records filled in by other professionals is unavoidable but tends to be less accurate. Fortunately, at the time of clinical assessment, although clinicians were not blinded to the full blood count, they were not aware of this hypothesis, thus diminishing diagnostic bias. Other potential risk factors associated with TB in mainly new patients have been described in other settings, such as health knowledge, distance to treatment center, and patients' economic status; these could not be evaluated in this study \[[@cit0033], [@cit0034]\].

In conclusion, the result of increased risk of NLR ≥ 2.53 on PTB retreatment was stable. NLR ≥ 2.53 is predictive of PTB retreatment. Additionally, the retreatment rate in PTB patients with NLR ≥ 2.53 was higher than in PTB patients with NLR \< 2.53. Other factors, especially initial cavitation on chest X-ray, history of smoking, and age ≥ 60, also had higher risk for retreatment. Due to the large number of PTB patients and the limited cure rate for PTB retreatment in China, the high cost of retreatment should not be ignored. We recommend that, upon completion of anti-TB treatment, follow-up strategies targeting PTB patients with NLR ≥ 2.53 must pay more attention to avoid TB relapse, treatment default and abandonment related to retreatment early. Moreover, further studies of chest X-ray monitoring are needed in PTB patients with initial cavitation to control the risk of retreatment. Adequate blood test and chest X-ray monitoring in PTB patients in this cohort study were highlighted to avoid PTB retreatment, issues requiring urgent attention.
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